Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Drug"" wg kryterium: Temat


Tytuł :
NICEdrug.ch, a workflow for rational drug design and systems-level analysis of drug metabolism.
Autorzy :
MohammadiPeyhani H; Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de Lausanne, EPFL, Lausanne, Switzerland.
Chiappino-Pepe A; Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de Lausanne, EPFL, Lausanne, Switzerland.
Haddadi K; Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de Lausanne, EPFL, Lausanne, Switzerland.
Hafner J; Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de Lausanne, EPFL, Lausanne, Switzerland.
Hadadi N; Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de Lausanne, EPFL, Lausanne, Switzerland.
Hatzimanikatis V; Laboratory of Computational Systems Biotechnology, École Polytechnique Fédérale de Lausanne, EPFL, Lausanne, Switzerland.
Pokaż więcej
Źródło :
ELife [Elife] 2021 Aug 03; Vol. 10. Date of Electronic Publication: 2021 Aug 03.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Design*
Drug Repositioning*
Drug Discovery/*methods
Pharmaceutical Preparations/*metabolism
Animals ; Antimetabolites, Antineoplastic/chemistry ; Antimetabolites, Antineoplastic/metabolism ; Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; COVID-19/drug therapy ; Databases, Pharmaceutical ; Drug-Related Side Effects and Adverse Reactions/etiology ; Drug-Related Side Effects and Adverse Reactions/metabolism ; Fluorouracil/chemistry ; Fluorouracil/metabolism ; Humans ; Pharmaceutical Preparations/chemistry ; Workflow
Czasopismo naukowe
Tytuł :
COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach.
Autorzy :
Abd El Hadi SR; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt.
Zien El-Deen EE; Pharmaceutical Technology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.; Pharmaceutics Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt.
Bahaa MM; Pharmacy Practice Department, Faculty of Pharmacy, Horus University, New Damietta, Egypt.
Sadakah AA; Oral and Maxillofacial Surgery, Department, Faculty of Dentistry, Tanta University, Tanta, Egypt.; Oral and Maxillofacial Surgery, Department, Faculty of Dentistry, AlSalam University, Tanta, Egypt.
Yassin HA; Pharmaceutics Department. Faculty of Pharmacy, AlSalam University, Tanta, Egypt.
Pokaż więcej
Źródło :
Drug design, development and therapy [Drug Des Devel Ther] 2021 Jul 30; Vol. 15, pp. 3313-3330. Date of Electronic Publication: 2021 Jul 30 (Print Publication: 2021).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Carriers*
Drug Repositioning*
Models, Molecular*
Antiviral Agents/*administration & dosage
COVID-19/*drug therapy
COVID-19 Vaccines/*administration & dosage
Animals ; Antiviral Agents/chemistry ; COVID-19/epidemiology ; COVID-19/immunology ; COVID-19/virology ; COVID-19 Vaccines/chemistry ; Drug Compounding ; Host-Pathogen Interactions ; Humans ; Nanoparticles ; SARS-CoV-2/drug effects ; SARS-CoV-2/pathogenicity ; Vaccination
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay.
Autorzy :
Jang WD; Metabolic and Biomolecular Engineering National Research Laboratory, Department of Chemical and Biomolecular Engineering (BK21 four), KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.; Systems Metabolic Engineering and Systems Healthcare Cross-Generation Collaborative Laboratory, KAIST, Daejeon 34141, Republic of Korea.
Jeon S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Republic of Korea.
Kim S; Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam 13488, Republic of Korea; .
Lee SY; Metabolic and Biomolecular Engineering National Research Laboratory, Department of Chemical and Biomolecular Engineering (BK21 four), KAIST Institute for the BioCentury, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea; .; Systems Metabolic Engineering and Systems Healthcare Cross-Generation Collaborative Laboratory, KAIST, Daejeon 34141, Republic of Korea.; KAIST Institute for Artificial Intelligence, BioProcess Engineering Research Center, BioInformatics Research Center, KAIST, Daejeon 34141, Republic of Korea.
Pokaż więcej
Źródło :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2021 Jul 27; Vol. 118 (30).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Repositioning*
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Animals ; Chlorocebus aethiops ; Drug Evaluation, Preclinical ; Drug Synergism ; Humans ; User-Computer Interface ; Vero Cells
Czasopismo naukowe
Tytuł :
Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data.
Autorzy :
Yee SW; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Vora B; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Oskotsky T; Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.
Zou L; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Jakobsen S; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Enogieru OJ; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Koleske ML; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Kosti I; Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.
Rödin M; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Sirota M; Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, California, USA.
Giacomini KM; Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2021 Jul; Vol. 110 (1), pp. 108-122. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article
MeSH Terms :
Antiviral Agents*/pharmacokinetics
COVID-19*/drug therapy
COVID-19*/virology
Drug Interactions*
Drug-Related Side Effects and Adverse Reactions*/etiology
Drug-Related Side Effects and Adverse Reactions*/metabolism
Drug-Related Side Effects and Adverse Reactions*/prevention & control
Membrane Transport Proteins/*metabolism
Virus Internalization/*drug effects
Virus Replication/*drug effects
Clinical Trials as Topic ; Drug Monitoring/methods ; Drug Monitoring/standards ; Electronic Health Records/statistics & numerical data ; HEK293 Cells ; Humans ; Hydroxychloroquine/pharmacokinetics ; Risk Assessment/methods ; SARS-CoV-2/drug effects ; SARS-CoV-2/physiology
Czasopismo naukowe
Tytuł :
P53 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma.
Autorzy :
Sekino Y; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan; .
Takemoto K; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Murata D; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Babasaki T; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kobatake K; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kitano H; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Ikeda K; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Goto K; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Inoue S; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hayashi T; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Taniyama D; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Shigeta M; Department of Urology, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Kuraoka K; Department of Diagnostic Pathology, National Hospital Organization, Kure Medical Center and Chugoku Cancer Center, Kure, Japan.
Mita K; Department of Urology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
Kaneko M; Department of Diagnostic Pathology, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan.
Sentani K; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Oue N; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Teishima J; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Pokaż więcej
Źródło :
Anticancer research [Anticancer Res] 2021 Sep; Vol. 41 (9), pp. 4287-4294.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Resistance, Neoplasm*
Up-Regulation*/drug effects
Carcinoma, Renal Cell/*drug therapy
Imidazoles/*pharmacology
Kidney Neoplasms/*drug therapy
Piperazines/*pharmacology
Sunitinib/*pharmacology
Tumor Suppressor Protein p53/*genetics
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Renal Cell/genetics ; Carcinoma, Renal Cell/metabolism ; Cell Proliferation/drug effects ; Computer Simulation ; Drug Synergism ; Female ; Gene Knockout Techniques ; Humans ; Kaplan-Meier Estimate ; Kidney Neoplasms/genetics ; Kidney Neoplasms/metabolism ; Male ; Middle Aged ; Progression-Free Survival ; Retrospective Studies ; Treatment Outcome ; Tumor Suppressor Protein p53/metabolism
Czasopismo naukowe
Tytuł :
Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab.
Autorzy :
Rabinovici GD; From the Department of Neurology, the Department of Radiology and Biomedical Imaging, and the Weill Institute for Neurosciences, University of California San Francisco, San Francisco.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2021 Aug 26; Vol. 385 (9), pp. 771-774. Date of Electronic Publication: 2021 Jul 28.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Approval*
Plaque, Amyloid*/drug therapy
Alzheimer Disease/*drug therapy
Amyloid beta-Peptides/*antagonists & inhibitors
Antibodies, Monoclonal, Humanized/*therapeutic use
Alzheimer Disease/diagnosis ; Biomarkers ; Drug Industry/ethics ; Humans ; Interprofessional Relations ; Positron-Emission Tomography ; Time Factors ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era.
Autorzy :
Ferreira-da-Silva R; Porto Pharmacovigilance Centre, Rua Doutor Plácido da Costa, 4200-450, Porto, Portugal. .; Department of Community Medicine, Health Information and Decision, Porto, Portugal. .; CINTESIS - Center for Health Technology and Services Research, Porto, Portugal. .
Ribeiro-Vaz I; Porto Pharmacovigilance Centre, Rua Doutor Plácido da Costa, 4200-450, Porto, Portugal.; Department of Community Medicine, Health Information and Decision, Porto, Portugal.; CINTESIS - Center for Health Technology and Services Research, Porto, Portugal.
Morato M; Department of Drug Sciences, LAQV/REQUIMTE, Laboratory of Pharmacology, Porto, Portugal.
Polónia JJ; Porto Pharmacovigilance Centre, Rua Doutor Plácido da Costa, 4200-450, Porto, Portugal.; CINTESIS - Center for Health Technology and Services Research, Porto, Portugal.; Department of Medicine, University of Porto, Porto, Portugal.
Pokaż więcej
Źródło :
International journal of clinical pharmacy [Int J Clin Pharm] 2021 Aug; Vol. 43 (4), pp. 1133-1138. Date of Electronic Publication: 2021 Jun 02.
Typ publikacji :
Journal Article
MeSH Terms :
Adverse Drug Reaction Reporting Systems*/organization & administration
Pharmacovigilance*
Antiviral Agents/*adverse effects
COVID-19/*drug therapy
Antiviral Agents/therapeutic use ; COVID-19/epidemiology ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/etiology ; Humans ; Patient Safety ; SARS-CoV-2/drug effects
Czasopismo naukowe
Tytuł :
Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Autorzy :
Yang L; Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Pei RJ; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
Li H; Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; University of Chinese Academy of Sciences, Beijing, 100049, China.
Ma XN; Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Zhou Y; Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Zhu FH; Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
He PL; Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Tang W; Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Zhang YC; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
Xiong J; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
Xiao SQ; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China.
Tong XK; Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. .
Zhang B; Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, 430071, China. .
Zuo JP; Laboratory of Immunopharmacology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. .; University of Chinese Academy of Sciences, Beijing, 100049, China. .; Laboratory of Immunology and Virology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. .
Pokaż więcej
Źródło :
Acta pharmacologica Sinica [Acta Pharmacol Sin] 2021 Aug; Vol. 42 (8), pp. 1347-1353. Date of Electronic Publication: 2020 Oct 28.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Repositioning*
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
SARS-CoV-2/*drug effects
Virus Internalization/*drug effects
Cell Line ; Drug Approval ; High-Throughput Screening Assays ; Humans ; Microbial Sensitivity Tests ; SARS-CoV-2/physiology ; Spike Glycoprotein, Coronavirus/drug effects
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
A new biodegradable nano cellulose-based drug delivery system for pH-controlled delivery of curcumin.
Autorzy :
Anirudhan TS; Department of Chemistry, Research Centre, School of Physical and Mathematical Sciences, University of Kerala, Kariavattom, Trivandrum 695 581, India. Electronic address: .
Manjusha V; Department of Chemistry, Research Centre, School of Physical and Mathematical Sciences, University of Kerala, Kariavattom, Trivandrum 695 581, India.
Chithra Sekhar V; Department of Chemistry, Research Centre, School of Physical and Mathematical Sciences, University of Kerala, Kariavattom, Trivandrum 695 581, India.
Pokaż więcej
Źródło :
International journal of biological macromolecules [Int J Biol Macromol] 2021 Jul 31; Vol. 183, pp. 2044-2054. Date of Electronic Publication: 2021 Jun 04.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Carriers*
Nanoparticles*
Antineoplastic Agents, Phytogenic/*pharmacology
Breast Neoplasms/*drug therapy
Cellulose/*chemical synthesis
Curcumin/*pharmacology
Animals ; Antineoplastic Agents, Phytogenic/toxicity ; Apoptosis/drug effects ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Cell Survival/drug effects ; Cellulose/analogs & derivatives ; Cellulose/toxicity ; Cerium/chemistry ; Chick Embryo ; Cross-Linking Reagents/chemistry ; Curcumin/chemistry ; Curcumin/toxicity ; Delayed-Action Preparations ; Drug Compounding ; Drug Liberation ; Epoxy Compounds/chemistry ; Female ; Folic Acid/chemistry ; Humans ; Hydrogen-Ion Concentration ; Methacrylates/chemistry ; Sulfates/chemistry
Czasopismo naukowe
Tytuł :
Synthesis and characterization of chitosan/polyvinylpyrrolidone coated nanoporous γ-Alumina as a pH-sensitive carrier for controlled release of quercetin.
Autorzy :
Nematollahi E; School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Pourmadadi M; Department of Life Science Engineering, Faculty of New Science and Technologies, University of Tehran, Tehran, Iran.
Yazdian F; Department of Life Science Engineering, Faculty of New Science and Technologies, University of Tehran, Tehran, Iran. Electronic address: .
Fatoorehchi H; School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran. Electronic address: .
Rashedi H; Department of Biotechnology, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran.
Nigjeh MN; Pharmaceutical Sciences Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran.
Pokaż więcej
Źródło :
International journal of biological macromolecules [Int J Biol Macromol] 2021 Jul 31; Vol. 183, pp. 600-613. Date of Electronic Publication: 2021 Apr 28.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Carriers*
Nanopores*
Aluminum Oxide/*pharmacology
Antineoplastic Agents, Phytogenic/*pharmacology
Apoptosis/*drug effects
Breast Neoplasms/*drug therapy
Chitosan/*chemical synthesis
Povidone/*chemical synthesis
Quercetin/*pharmacology
Aluminum Oxide/chemistry ; Antineoplastic Agents, Phytogenic/chemistry ; Breast Neoplasms/pathology ; Chitosan/analogs & derivatives ; Delayed-Action Preparations ; Drug Compounding ; Drug Liberation ; Female ; Humans ; Hydrogen-Ion Concentration ; Kinetics ; MCF-7 Cells ; Povidone/analogs & derivatives ; Quercetin/chemistry
Czasopismo naukowe
Tytuł :
Fabrication and antibacterial evaluation of peppermint oil-loaded composite microcapsules by chitosan-decorated silica nanoparticles stabilized Pickering emulsion templating.
Autorzy :
Lai H; Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, 1688 Meiling Avenue, Nanchang 330004, China.
Liu Y; Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, 1688 Meiling Avenue, Nanchang 330004, China.
Huang G; Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, 1688 Meiling Avenue, Nanchang 330004, China.
Chen Y; Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, 1688 Meiling Avenue, Nanchang 330004, China.
Song Y; Laboratory Animal Science and Technology Center, Jiangxi University of Chinese Medicine, 1688 Meiling Avenue, Nanchang 330004, China.
Ma Y; Department of Pharmacy, The 908th Hospital of People's Liberation Army, Nanchang, China.
Yue P; Key Lab of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, 1688 Meiling Avenue, Nanchang 330004, China. Electronic address: .
Pokaż więcej
Źródło :
International journal of biological macromolecules [Int J Biol Macromol] 2021 Jul 31; Vol. 183, pp. 2314-2325. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Carriers*
Nanoparticles*
Anti-Bacterial Agents/*pharmacology
Chitosan/*chemistry
Escherichia coli/*drug effects
Plant Oils/*pharmacology
Silicon Dioxide/*chemistry
Staphylococcus aureus/*drug effects
Adsorption ; Anti-Bacterial Agents/chemistry ; Capsules ; Delayed-Action Preparations ; Drug Compounding ; Drug Liberation ; Drug Stability ; Emulsions ; Escherichia coli/growth & development ; Hydrophobic and Hydrophilic Interactions ; Hypromellose Derivatives/chemistry ; Plant Oils/chemistry ; Staphylococcus aureus/growth & development ; Time Factors
Czasopismo naukowe
Tytuł :
Optimally designed theranostic system based folic acids and chitosan as a promising mucoadhesive delivery system for encapsulating curcumin LbL nano-template against invasiveness of breast cancer.
Autorzy :
Hanafy NAN; Nanomedicine Group, Institute of Nanoscience and Nanotechnology, Kafrelsheikh University, 33516 Kafrelsheikh, Egypt. Electronic address: .
Pokaż więcej
Źródło :
International journal of biological macromolecules [Int J Biol Macromol] 2021 Jul 01; Vol. 182, pp. 1981-1993. Date of Electronic Publication: 2021 May 28.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Compounding*
Drug Delivery Systems*
Theranostic Nanomedicine*
Breast Neoplasms/*drug therapy
Chitosan/*chemistry
Curcumin/*therapeutic use
Folic Acid/*chemistry
Nanoparticles/*chemistry
Adhesiveness ; Adsorption ; Apoptosis ; Breast Neoplasms/pathology ; Breast Neoplasms/ultrastructure ; Cell Cycle Checkpoints/drug effects ; Cell Death ; Cell Shape ; Curcumin/chemistry ; Curcumin/pharmacology ; Drug Liberation ; Female ; Humans ; Hydrogen-Ion Concentration ; MCF-7 Cells ; Nanoparticles/ultrastructure ; Necrosis ; Neoplasm Invasiveness ; Spectrophotometry, Ultraviolet ; Spectroscopy, Fourier Transform Infrared ; Static Electricity ; Stereoisomerism
Czasopismo naukowe
Tytuł :
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: week 48 results of a single-arm, open-label, multicentre, phase 2/3 trial.
Autorzy :
Gaur AH; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: .
Cotton MF; Department of Paediatrics and Child Health, Family Centre for Research with Ubuntu, Stellenbosch University, Tygerberg Hospital, Cape Town, South Africa.
Rodriguez CA; Department of Pediatrics, Division of Infectious Diseases, Morsani College of Medicine, University of South Florida, Tampa, FL, USA.
McGrath EJ; Department of Pediatrics, School of Medicine, Wayne State University, Detroit, MI, USA.
Helström E; Be Part Yoluntu Centre, Western Cape, South Africa.
Liberty A; Chris Hani Baragwanath Academic Hospital, Soweto, South Africa.
Natukunda E; Joint Clinical Research Centre, Kampala, Uganda.
Kosalaraksa P; Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Chokephaibulkit K; Department of Pediatrics and Siriraj Institute of Clinical Research, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Maxwell H; Department of Portfolio Project Management, Gilead Sciences, Foster City, CA, USA.
Wong P; Department of Biometrics, Gilead Sciences, Foster City, CA, USA.
Porter D; Department of Virology, Gilead Sciences, Foster City, CA, USA.
Majeed S; Department of Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA.
Yue MS; Department of Clinical Pharmacology, Gilead Sciences, Foster City, CA, USA.
Graham H; Department of Virology Clinical Research, Gilead Sciences, Foster City, CA, USA.
Martin H; Department of Virology Clinical Research, Gilead Sciences, Foster City, CA, USA.
Brainard DM; Department of Virology Clinical Research, Gilead Sciences, Foster City, CA, USA.
Pikora C; Department of Virology Clinical Research, Gilead Sciences, Foster City, CA, USA.
Pokaż więcej
Źródło :
The Lancet. Child & adolescent health [Lancet Child Adolesc Health] 2021 Sep; Vol. 5 (9), pp. 642-651. Date of Electronic Publication: 2021 Jul 22.
Typ publikacji :
Clinical Trial; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Alanine*/administration & dosage
Alanine*/adverse effects
Alanine*/pharmacokinetics
Anti-Retroviral Agents*/administration & dosage
Anti-Retroviral Agents*/adverse effects
Anti-Retroviral Agents*/pharmacokinetics
Emtricitabine*/administration & dosage
Emtricitabine*/adverse effects
Emtricitabine*/pharmacokinetics
HIV Infections*/blood
HIV Infections*/drug therapy
HIV Infections*/virology
Drug Monitoring/*methods
Tenofovir/*analogs & derivatives
Adolescent ; Amides/administration & dosage ; Amides/adverse effects ; Amides/pharmacokinetics ; CD4 Lymphocyte Count/methods ; Child ; Drug Dosage Calculations ; Drug Therapy, Combination/methods ; Female ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Heterocyclic Compounds, 3-Ring/adverse effects ; Heterocyclic Compounds, 3-Ring/pharmacokinetics ; Humans ; Male ; Piperazines/administration & dosage ; Piperazines/adverse effects ; Piperazines/pharmacokinetics ; Pyridones/administration & dosage ; Pyridones/adverse effects ; Pyridones/pharmacokinetics ; Tenofovir/administration & dosage ; Tenofovir/adverse effects ; Tenofovir/pharmacokinetics ; Treatment Outcome ; Viral Load/methods
Czasopismo naukowe
Tytuł :
PARP inhibition in UV-associated angiosarcoma preclinical models.
Autorzy :
Weidema ME; Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. .
Desar IME; Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Hillebrandt-Roeffen MHS; Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
van Erp AEM; Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Masuzawa M; Department of Regulation Biochemistry, Kitasato University School of Allied Sciences, Sagamihara, Japan.
Flucke UE; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
van der Graaf WTA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Versleijen-Jonkers YMH; Department of Medical Oncology, Radboud University Medical Center, Internal Postal Code 452, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.
Pokaż więcej
Corporate Authors :
PALGA-group
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Sep; Vol. 147 (9), pp. 2579-2590. Date of Electronic Publication: 2021 Jun 03.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Synergism*
Ultraviolet Rays*
Hemangiosarcoma/*drug therapy
Nuclear Proteins/*metabolism
Poly (ADP-Ribose) Polymerase-1/*antagonists & inhibitors
Poly(ADP-ribose) Polymerase Inhibitors/*pharmacology
Temozolomide/*pharmacology
Antineoplastic Agents, Alkylating/pharmacology ; Apoptosis ; Cell Proliferation ; Drug Combinations ; Drug Evaluation, Preclinical ; Hemangiosarcoma/etiology ; Hemangiosarcoma/pathology ; Humans ; Poly (ADP-Ribose) Polymerase-1/metabolism ; Prognosis ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.
Autorzy :
von Hentig N; Sachsenhausen Practice of General Medicine, HIV-Focus, Frankfurt am Main, Germany. .; HIVCENTER, Internal Medicine II, Goethe University Hospital, Frankfurt am Main, Germany. .; Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany. .; Section Pharmacology, German AIDS Society, Frankfurt am Main, Germany. .; Praxis für Allgemeinmedizin / HIV-Schwerpunkt, Ziegelhüttenweg 1-3, 60598, Frankfurt am Main, Germany. .; HIVCENTER, Johann Wolfgang Goethe Universität, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany. .
Pokaż więcej
Źródło :
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2021 Sep; Vol. 77 (9), pp. 1297-1307. Date of Electronic Publication: 2021 Mar 04.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Repositioning*
Antiviral Agents/*therapeutic use
COVID-19/*drug therapy
ATP Binding Cassette Transporter, Subfamily B, Member 1/drug effects ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Antiviral Agents/pharmacology ; Clinical Trials as Topic ; Drug Combinations ; Drug Interactions ; HIV Protease Inhibitors/pharmacology ; HIV Protease Inhibitors/therapeutic use ; Humans ; Nucleosides/analogs & derivatives ; Nucleotides/pharmacology ; Nucleotides/therapeutic use ; Oxygen/blood ; SARS-CoV-2
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics.
Autorzy :
Liu SN; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Lu T; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Jin JY; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Li C; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Girish S; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Melnikov F; Department of Safety Assessment, Genentech, Inc., South San Francisco, California, USA.
Badovinac Crnjevic T; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Machackova Z; PDMA-Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Restuccia E; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Kirschbrown WP; Department of Clinical Pharmacology, Genentech, Inc., South San Francisco, California, USA.
Pokaż więcej
Źródło :
Journal of clinical pharmacology [J Clin Pharmacol] 2021 Aug; Vol. 61 (8), pp. 1096-1105. Date of Electronic Publication: 2021 Jul 07.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/pharmacokinetics
Dose-Response Relationship, Drug*
Time-to-Treatment*
Trastuzumab*/administration & dosage
Trastuzumab*/pharmacokinetics
Breast Neoplasms/*drug therapy
Maintenance Chemotherapy/*methods
Receptor, ErbB-2/*antagonists & inhibitors
Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; COVID-19/epidemiology ; COVID-19/prevention & control ; Computer Simulation ; Consolidation Chemotherapy/methods ; Drug Administration Routes ; Drug Administration Schedule ; Female ; Humans ; Infection Control/methods ; SARS-CoV-2
Czasopismo naukowe
Tytuł :
Impact of ciprofloxacin impurities on bacterial growth, antibiotic resistance development and content assays.
Autorzy :
Ching C; Department of Biomedical Engineering, Boston University, Boston, MA, USA.
Zaman MH; Department of Biomedical Engineering, Boston University, Boston, MA, USA.
Pokaż więcej
Źródło :
Letters in applied microbiology [Lett Appl Microbiol] 2021 Aug; Vol. 73 (2), pp. 220-228. Date of Electronic Publication: 2021 May 11.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Contamination*
Drug Resistance, Bacterial*
Ciprofloxacin/*pharmacology
Escherichia coli/*drug effects
Escherichia coli/*growth & development
Fluoroquinolones/*pharmacology
Anti-Bacterial Agents/pharmacology ; Ciprofloxacin/analogs & derivatives ; Drug Resistance, Microbial
Czasopismo naukowe
Tytuł :
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2.
Autorzy :
Tummino TA; Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, CA, USA.; Graduate Program in Pharmaceutical Sciences and Pharmacogenomics, UCSF, San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), UCSF, San Francisco, CA, USA.; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Rezelj VV; Institut Pasteur, Viral Populations and Pathogenesis Unit, CNRS UMR 3569, 75724 Paris, Cedex 15, France.
Fischer B; Novartis Institutes for BioMedical Research, Preclinical Safety, Basel, Switzerland.
Fischer A; Novartis Institutes for BioMedical Research, Preclinical Safety, Basel, Switzerland.
O'Meara MJ; Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
Monel B; Institut Pasteur, Virus and Immunity Unit, CNRS UMR 3569, 75724 Paris, Cedex 15, France.
Vallet T; Institut Pasteur, Viral Populations and Pathogenesis Unit, CNRS UMR 3569, 75724 Paris, Cedex 15, France.
White KM; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zhang Z; Quantitative Biosciences Institute (QBI), UCSF, San Francisco, CA, USA.; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, UCSF, San Francisco, CA, USA.; Howard Hughes Medical Institute, UCSF, San Francisco, CA, USA.
Alon A; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Schadt H; Novartis Institutes for BioMedical Research, Preclinical Safety, Basel, Switzerland.
O'Donnell HR; Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, CA, USA.
Lyu J; Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, CA, USA.; Quantitative Biosciences Institute (QBI), UCSF, San Francisco, CA, USA.; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Rosales R; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
McGovern BL; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Rathnasinghe R; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jangra S; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Schotsaert M; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Galarneau JR; Novartis Institutes for BioMedical Research, Preclinical Safety, Cambridge, MA, USA.
Krogan NJ; Quantitative Biosciences Institute (QBI), UCSF, San Francisco, CA, USA.; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, UCSF, San Francisco, CA, USA.; Gladstone Institute of Data Science and Biotechnology, J. David Gladstone Institutes, San Francisco, CA, USA.
Urban L; Novartis Institutes for BioMedical Research, Preclinical Safety, Cambridge, MA, USA.
Shokat KM; Quantitative Biosciences Institute (QBI), UCSF, San Francisco, CA, USA.; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, UCSF, San Francisco, CA, USA.; Howard Hughes Medical Institute, UCSF, San Francisco, CA, USA.
Kruse AC; Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
García-Sastre A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Schwartz O; Institut Pasteur, Virus and Immunity Unit, CNRS UMR 3569, 75724 Paris, Cedex 15, France.
Moretti F; Novartis Institutes for BioMedical Research, Preclinical Safety, Basel, Switzerland. .
Vignuzzi M; Institut Pasteur, Viral Populations and Pathogenesis Unit, CNRS UMR 3569, 75724 Paris, Cedex 15, France. .
Pognan F; Novartis Institutes for BioMedical Research, Preclinical Safety, Basel, Switzerland. .
Shoichet BK; Department of Pharmaceutical Chemistry, University of California San Francisco (UCSF), San Francisco, CA, USA. .; Quantitative Biosciences Institute (QBI), UCSF, San Francisco, CA, USA.; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Pokaż więcej
Źródło :
Science (New York, N.Y.) [Science] 2021 Jul 30; Vol. 373 (6554), pp. 541-547. Date of Electronic Publication: 2021 Jun 22.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Repositioning*
Antiviral Agents/*pharmacology
COVID-19/*drug therapy
Lipidoses/*chemically induced
Phospholipids/*metabolism
SARS-CoV-2/*drug effects
A549 Cells ; Animals ; Antiviral Agents/chemistry ; Antiviral Agents/therapeutic use ; Antiviral Agents/toxicity ; COVID-19/virology ; Cations ; Chlorocebus aethiops ; Dose-Response Relationship, Drug ; Female ; Humans ; Mice ; Microbial Sensitivity Tests ; SARS-CoV-2/physiology ; Surface-Active Agents/chemistry ; Surface-Active Agents/pharmacology ; Surface-Active Agents/toxicity ; Vero Cells ; Virus Replication/drug effects
SCR Protocol :
COVID-19 drug treatment
Czasopismo naukowe
Tytuł :
Engineered macrophages as near-infrared light activated drug vectors for chemo-photodynamic therapy of primary and bone metastatic breast cancer.
Autorzy :
Huang Y; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Guan Z; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Dai X; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Shen Y; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Wei Q; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Ren L; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Jiang J; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Xiao Z; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Jiang Y; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Liu D; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Huang Z; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Xu X; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Luo Y; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China.
Zhao C; School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, People's Republic of China. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2021 Jul 14; Vol. 12 (1), pp. 4310. Date of Electronic Publication: 2021 Jul 14.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Delivery Systems*
Bone Neoplasms/*drug therapy
Breast Neoplasms/*drug therapy
Macrophages/*transplantation
Photochemotherapy/*methods
Animals ; Apoptosis/drug effects ; B7-H1 Antigen/antagonists & inhibitors ; Bone Neoplasms/immunology ; Bone Neoplasms/secondary ; Breast Neoplasms/immunology ; Breast Neoplasms/pathology ; Cell Line, Tumor ; Cell Movement/drug effects ; Drug Carriers/chemistry ; Female ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunogenic Cell Death/drug effects ; Immunologic Memory/drug effects ; Indoles/administration & dosage ; Indoles/chemistry ; Indoles/pharmacology ; Infrared Rays ; Macrophages/chemistry ; Nanomedicine ; Organometallic Compounds/administration & dosage ; Organometallic Compounds/chemistry ; Organometallic Compounds/pharmacology ; Oxaliplatin/administration & dosage ; Oxaliplatin/chemistry ; Oxaliplatin/pharmacology ; Photosensitizing Agents/administration & dosage ; Photosensitizing Agents/chemistry ; Photosensitizing Agents/pharmacology ; Prodrugs/administration & dosage ; Prodrugs/chemistry ; Prodrugs/pharmacology
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies